We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mylan Pharmaceuticals, the generic branch of Mylan Laboratories, has received
tentative approval for its Oxybutynin Chloride extended-release tablets, 5
mg and 10 mg.
EntreMed has announced a published preclinical report supporting the use of
2-methoxyestradiol (2ME2) in combination with paclitaxel in the treatment
of recurrent or advanced head and neck squamous cell carcinoma (HNSCC).
Adherex Technologies has received regulatory approval from Swiss Medic to initiate
a Phase Ib/II clinical trial of its lead angiolytic compound Exherin in advanced
cancer patients who express the tumor molecular target N-cadherin.
Alteon has initiated a Phase II trial of its novel A.G.E. Crosslink Breaker
compound alagebrium chloride (formerly known as ALT-711) in erectile dysfunction
(ED).
BioSante Pharmaceuticals has reached its enrollment target of more than 450
women in the company's pivotal, Phase III clinical trial to evaluate the safety
and efficacy of Bio-E-Gel for the treatment of moderate-to-severe hot flashes
in menopausal women.
Spectrum Pharmaceuticals has received a notice of allowance from the U.S.
Patent and Trademark Office for its patent application for EOquin titled,
"Medical Compositions for Intravesical Treatment of Bladder Cancer."